Enough Will They-Won’t They! FDA Pushes for Permanent Rare Pediatric Disease PRVs

As any well-rounded consumer of television knows, one of the most ubiquitous tropes in sitcoms is the “will they-won’t they” dynamic.  Take your pick:  Ross and Rachel from Friends, Jim and Pam from The Office, or Mulder and Scully from The X-Files.  It’s riveting and exhausting.  FDA has grown similarly tired of Congress’s will they-won’t they decision-making when it comes to the reauthorization of the Rare Pediatric Disease (RPD) Priority Review Voucher (PRV) program.

In its FY2027 budget request (at 27), FDA has requested that Congress make the RPD PRV program permanent.  This proposal would end the familiar four-year reauthorization cycle that has repeatedly put the program at risk of lapsing and, from industry’s perspective, would provide much-welcomed and needed predictability for sponsors developing therapies for children with serious or life-threatening rare diseases.

First, a Quick Refresher on the RPD PRV Program

Section 529 of the FD&C Act authorizes FDA to award a priority review voucher to sponsors of certain approved rare pediatric disease products.  A voucher allows the holder to redeem priority review for another application, shortening FDA’s review clock from the standard 10 months to 6 months.  Therapies that are eligible to receive an RPD PRV must contain a new active moiety and target a serious or life-threatening rare pediatric disease, among other things.  See FDA’s dedicated website, Rare Pediatric Disease Designation and Priority Review Voucher Programs, and draft guidance, “Rare Pediatric Disease Priority Review Vouchers.”  The vouchers are transferable and can be extremely valuable—often selling for hundreds of millions of dollars—creating a financial incentive to invest in treatments that might otherwise be commercially challenging or unviable.  To demonstrate the potential financial windfall these vouchers can bring, look no further than Cyprium Therapeutics.  The Fortress Biotech Inc. subsidiary recently sold its RPD PRV for $205 million.

Historically, Congress has reauthorized the program every four years.  That cadence has created recurring uncertainty; the program even briefly expired in 2024 before being renewed again this past February via the Consolidated Appropriations Act of 2026.  See our previous blog post here.  If nothing changes, it is currently set to expire in September 2029.  See our previous coverage of the program’s recent tumultuous, uncertain status and ultimate reauthorization here, here, here, and here.

Why does FDA want Permanence?

I mean, who wouldn’t?  Have you ever heard of a professor turning down tenure or the Harlem Globetrotters losing to the Washington Generals?  Everyone wants a sure thing.  Note:  Please don’t email the authors about the Globetrotters’ 1971 loss to the New Jersey Reds, the predecessors to the Generals—no one likes a know-it-all.

Kidding aside, permanent authorization would prevent future cliffhangers tied to the congressional budget cycle and help ensure that children with debilitating or life-threatening conditions continue to gain access to new therapies.  We saw many of our own clients face struggles in receiving infusions of investment for continued development as the prior September 2026 sunset loomed.  Sadly, certain applications were submitted more rapidly and perhaps without the degree of prior FDA interaction that would be typical to consider data from a rare disease setting, in order to have their NDA/BLA action date fall ahead of the sunset.  Whether early in development or even at completion, the sunset of this vital program had a ripple effect across industry.

What You Should be Watching?

Permanent reauthorization would mark a significant policy shift for a program that has long lived on periodic congressional renewals.  For industry, it could reduce regulatory uncertainty and strengthen incentives for rare pediatric drug development.  Drug development requires long-term investment with a 10-15 year runway to get from bench to bedside.  The potential for PRV eligibility is important to secure investment that allows products to get licensed from researchers to move into GLP toxicology studies and then into first-in-human clinical trials, and remains an important factor for advancing products through each phase of development.  Development of drugs for rare diseases already is a challenging case to make when the development paths are typically so uncertain themselves with equally uncertain regulatory acceptance.  This is why having a certain regulatory/developmental “carrot” in the RPD PRV program is so important.

For Congress, however, it raises the perennial question of whether the PRV model is delivering sufficient public-health return on investment.

As the FY2027 budget process unfolds, stakeholders across the rare disease landscape will be watching closely to see whether the RPD PRV program finally escapes the reauthorization cycle—or faces another cliffhanger countdown to expiration.

We will continue to monitor FDA’s budget requests and report back on any developments.